NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: ER+-beta
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express ESR2 or Estrogen Receptor-beta
Exclusions: 
https://ClinicalTrials.gov/show/NCT03941730

Comments are closed.

Up ↑